Long noncoding (lnc)RNAs have been implicated in the development and progression of atherosclerosis. However, the expression and mechanism of action of lncRNAs in atherosclerosis are still unclear. We implemented microarray analysis in human advanced atherosclerotic plaques and normal arterial intimae to detect the lncRNA and mRNA expression profile. Gene Ontology functional enrichment and pathway analyses were applied to explore the potential functions and pathways involved in the pathogenesis of atherosclerosis. A total of 236 lncRNAs and 488 mRNAs were selected for further Ingenuity Pathway Analysis. Moreover, quantitative RT-PCR tests of most selected lncRNAs and mRNAs with high fold changes were consistent with the microarray data. We also performed ELISA to investigate the corresponding proteins levels of selected genes and showed that serum levels of SPP1, CD36, ATP6V0D2, CHI3L1, MYH11, and BDNF were differentially expressed in patients with coronary heart disease compared with healthy subjects. These proteins correlated with some biochemical parameters used in the diagnosis of cardiovascular diseases. Furthermore, receiver operating characteristic analysis showed a favorable diagnostic performance. The microarray profiling analysis and validation of differentially-expressed lncRNAs and mRNAs in atherosclerosis not only provide new insights into the pathogenesis of this disease but may also reveal new biomarkers for its diagnosis and treatment.

中文翻译：

---

新型长非编码 RNA 和 mRNA 作为潜在生物标志物及其在动脉粥样硬化中的功能的微阵列分析和验证。


长链非编码 (lnc)RNA 与动脉粥样硬化的发生和进展有关。然而，lncRNA在动脉粥样硬化中的表达和作用机制仍不清楚。我们对人类晚期动脉粥样硬化斑块和正常动脉内膜进行了微阵列分析，以检测 lncRNA 和 mRNA 表达谱。应用基因本体功能富集和通路分析来探索动脉粥样硬化发病机制中的潜在功能和通路。总共选择了 236 个 lncRNA 和 488 个 mRNA 进行进一步的 Ingenuity Pathway 分析。此外，大多数选定的具有高倍数变化的lncRNA和mRNA的定量RT-PCR测试与微阵列数据一致。我们还进行了 ELISA 检测所选基因的相应蛋白水平，结果显示，与健康受试者相比，冠心病患者的血清 SPP1、CD36、ATP6V0D2、CHI3L1、MYH11 和 BDNF 水平存在差异表达。这些蛋白质与心血管疾病诊断中使用的一些生化参数相关。此外，接收者操作特征分析显示出良好的诊断性能。动脉粥样硬化中差异表达的lncRNA和mRNA的微阵列分析和验证不仅为该疾病的发病机制提供了新的见解，而且还可能揭示其诊断和治疗的新生物标志物。